ArticleBMC pulmonary medicine2026
Trends in mortality involving coexisting lung cancer and sepsis in the United States: a CDC WONDER analysis, 1999-2024.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer and sepsis are major contributors to morbidity and mortality worldwide. Their coexistence represents a significant clinical challenge, as patients with lung cancer may be at increased risk of developing sepsis because of cancer-related immune dysfunction, treatment-related immunosuppression, and frequent healthcare exposure. Sepsis in these patients is associated with poor outcomes, increased health care utilization, and higher mortality rates.
methodsWe conducted a retrospective analysis of death certificates from the Centers for Disease Control and Prevention (CDC) WONDER database to evaluate mortality associated with the co-occurrence of lung cancer and sepsis among adults aged ≥ 45 years in the United States from 1999 to 2024. Age-adjusted mortality rates (AAMRs) and annual percent changes (APCs) were calculated and stratified by year, sex, race/ethnicity, census region, state, and metropolitan status.
resultsAAMR increased from 1.6 to 2.0 per 100,000 population between 1999 and 2024. Among males, the AAMR increased from 2.3 in 1999 to 2.4 in 2024, while among females, it rose from 1.1 to 1.6 over the same period. Racial disparities were evident, with non-Hispanic Black or African American adults experiencing the highest AAMR (2.6). Regionally, the South had the highest mortality burden (AAMR 2.2), while Kentucky and Mississippi reported the highest state-level rates (3.98 and 3.14, respectively). Mortality rates were higher in non-metropolitan areas (AAMR 1.9) compared with metropolitan areas (1.7).
conclusionsMortality associated with coexisting lung cancer and sepsis has increased over time, with notable disparities across demographic and geographic groups. These findings highlight the need for targeted public health strategies and improved access to care to reduce mortality in high-risk populations.
Indexed as
Identifiers
42458367What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.